Search Results 121-130 of 15374 for TNF
... TNF-α apoptotic pathway, 2)alternative splicing, tipping the balance towards pro-apoptotic as opposed to anti-apoptotic isoforms, and 3)inhibition of the ...
... Tumor Necrosis-Factor-Alpha Therapy (anti-TNF α) agent; Effective contraception from screening and for 36 weeks after the last dose of investigational ...
Role of TNF-receptor apoptosis inducing ligand (TRAIL) and hepatocyte apoptosis during co-infection. Significance to patient care. Although there have been ...
Two are the tumor necrosis factor inhibitors adalimumab, or Humira, and infliximab, or Remicade. These medicines work by dampening part of the immune system ...
Also known as biologic response modifiers, this newer class of drugs includes tumor necrosis factor (TNF) blockers, such as etanercept (Enbrel, Erelzi ...
Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns ...
Has had previous treatment with tumor necrosis factor- alpha (TNF-alpha) antagonists without documented clinical response to treatment (example, due to lack ...
... TNF alpha agents. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
... TNF or IL-17 inhibitors or IL-23 inhibitors). The anti-TNF- α, IL-17 inhibitors or IL-23 inhibitors should have been discontinued for a minimum washout period.
Participation eligibility · TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab, or infliximab) · Abatacept (Orencia; IV or SC) · Tocilizumab (Actemra; ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.